Vident Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

Vident Advisory's VRTX Position: Q2 2026 in Review

Vident Advisory reduced its Vertex Pharmaceuticals (VRTX) stake by 22% in Q2 2026, selling an estimated $1.57M and leaving 12,522 shares worth $6.22M. The position accounts for 0.04% of the portfolio, ranked #340.

Vident Advisory first reported a position in VRTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $21.5M in Q1 2024. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

• Vident Advisory held 12,522 shares of Vertex Pharmaceuticals worth $6.22M as of Q2 2026.
• Vident Advisory sold 3,541 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.57M.
• Vertex Pharmaceuticals made up 0.04% of Vident Advisory's portfolio in Q2 2026, its #340 holding.
• Vident Advisory first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
• Vident Advisory's Vertex Pharmaceuticals position peaked at $21.5M in Q1 2024.
• 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.